Praziquantel 40 mg/kg multiple doses vs single dose
Adverse events · patients with treating urinary schistosomiasis
1 finding from 1 review
- no estimate extracted1 study · 43 participantsVery low
Findings
What do systematic reviews say?
51 questions · 56 findings · 27 reviews
No studies found 2 · 3.6%GRADE not reported 3 · 5.4%Very low 9 · 16.1%Low 19 · 33.9%Moderate 17 · 30.4%High 6 · 10.7%
Summary of findings: multiple categories of exercise vs control (e.g. usual activities)
Adverse events · Older people living in the community (trials focusing on people recently discharged from hospital were not included)
1 finding from 1 review
- Exercise for preventing falls in older people living in the community 2019 · Cochrane Headline outcomes onlyno estimate extracted10 studies · 1177 participantsVery low
Are disease‐modifying drugs for a first attack suggestive of multiple sclerosis (MS) effective and safe vs placebo?
Discontinuation of medication due to adverse events
It is very uncertain whether are disease‐modifying drugs for a first attack suggestive of… changes withdrawls or drug discontinuation due to adverse events during 24… compared with placebo? (very low certainty).
1 finding from 1 review
- Treatment with disease‐modifying drugs for people with a first clinical attack suggestive of multiple sclerosis 2017 · Cochrane Headline outcomes onlyOR 2.43 [0.91, 6.49]Studies not reportedVery low
Intrauterine infusion/injection of autologous platelet‐rich plasma vs placebo or no intervention
Adverse event ‐ multiple pregnancy · women undergoing assisted reproduction
It is very uncertain whether intrauterine infusion/injection of autologous platelet‐rich plasma changes adverse events: multiple pregnancy compared with no intervention or placebo (very low certainty).
1 finding from 1 review
- OR 2.68 [0.81, 8.88]2 studies · 240 participantsVery low
Chinese herbal medicine (CHM) + follicle aspiration + ovulation induction vs follicle aspiration + ovulation induction
Adverse event ‐ multiple pregnancy · subfertile women with PCOS
It is very uncertain whether chinese herbal medicine (CHM) plus follicle aspiration plus… changes multiple pregnancy (adverse events) compared with follicle aspiration plus ovulation induction (very low certainty).
1 finding from 1 review
- Chinese herbal medicine for subfertile women with polycystic ovarian syndrome 2021 · Cochrane Headline outcomes onlyPeto OR 0.6 [0.06, 6.14]1 study · 44 participantsVery low
Intervention not reported
Adverse events ‐ Multiple pregnancy · women with subfertility
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Antioxidants vs Placebo, no intervention or usual care (with or without placebo)
Adverse event ‐ multiple pregnancy · women with subfertility
Antioxidant(s) showed no clear difference in adverse events ‐ Multiple pregnancy№ of participants: 1886(9 RCTs) compared with placebo or no treatment/standard treatment (low certainty).
1 finding from 1 review
- OR 1 [0.63, 1.56]Studies not reportedLow
Information provision vs (Optimised) usual care
Adverse events · people with multiple sclerosis
1 finding from 1 review
- no estimate extracted7 studies · 751 participantsModerate
Intervention not reported
Minor adverse events · [People] with [Multiple Sclerosis]
1 finding from 1 review
- no estimate extracted8 studies · 701 participantsLow
Intervention not reported
Serious adverse events · newly diagnosed, transplant‐ineligible adults with symptomatic multiple myeloma
The review found no eligible studies for this question.
1 finding from 1 review
- Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with… 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Intervention not reported
Serious adverse events · [People] with [Multiple Sclerosis]
1 finding from 1 review
- no estimate extracted8 studies · 621 participantsLow
Intervention not reported
Serious adverse events · People with multiple sclerosis
1 finding from 1 review
- no estimate extracted9 studies · 531 participantsGRADE not reported
Bortezomib vs no bortezomib
Diarrhoea · All patients with a diagnosis of multiple myeloma
Bortezomib may leads to higher adverse Events: Diarrhoea compared with no bortezomib (low certainty).
3 findings from 1 review
- OR 2.44 [1.74, 3.43]8 studies · 3788 participantsLow
- OR 6.24 [2.79, 13.98]4 studies · 1670 participantsModerate
- OR 1.8 [1.22, 2.65]4 studies · 2118 participantsModerate
Albendazole 400 mg single dose vs albendazole 400 mg multiple doses
Adverse events · children and adults
1 finding from 1 review
- no estimate extracted3 studies · 316 participantsModerate
Decompressive surgery plus radiotherapy vs radiotherapy
Adverse events · adults with metastatic extradural spinal cord compression (fit for surgery, paraplegic less than 48 hours, and without multiple discrete…
1 finding from 1 review
- Interventions for the treatment of metastatic extradural spinal cord compression in adults 2015 · Cochrane Headline outcomes onlyno estimate extracted1 study · 101 participantsGRADE not reported
Bortezomib vs no bortezomib
Thrombocytopenia · All patients with a diagnosis of multiple myeloma
Bortezomib may leads to higher adverse Events: Thrombocytopenia compared with no bortezomib (low certainty).
3 findings from 1 review
- OR 2.05 [1.7, 2.48]8 studies · 3791 participantsLow
- OR 1.51 [1.13, 2]3 studies · 1196 participantsHigh
- OR 2.6 [2.01, 3.35]5 studies · 2595 participantsLow
Bortezomib vs no bortezomib
Adverse Events: Infections (All) · All patients with a diagnosis of multiple myeloma
Bortezomib probably leads to higher adverse Events: Infections (All) compared with no bortezomib (moderate certainty).
1 finding from 1 review
- OR 1.51 [1.27, 1.79]9 studies · 4266 participantsModerate
Intervention not reported
Withdrawals due to adverse events · newly diagnosed, transplant‐ineligible adults with symptomatic multiple myeloma
1 finding from 1 review
- Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with… 2019 · Cochrane Headline outcomes onlyno estimate extracted82 participantsGRADE not reported
Fingolimod 0.5 mg vs interferon beta‐1a
Withdrawals due to adverse events · patients with relapsing‐remitting multiple sclerosis
Fingolimod 0.5 mg showed no clear difference in withdrawals due to adverse events compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
- RR 1.51 [0.81, 2.8]1 study · 860 participantsModerate
Fingolimod 0.5 mg vs placebo
Withdrawals due to adverse events · patients with relapsing‐remitting multiple sclerosis
It is very uncertain whether fingolimod 0.5 mg changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
- RR 1.42 [0.89, 2.25]2 studies · 1556 participantsVery low